InflaRx develops monoclonal antibodies and small-molecule inhibitors that selectively target the C5a complement protein and its receptor to treat inflammatory conditions. Its lead product vilobelimab has received emergency use authorization for certain hospitalized COVID-19 patients requiring mechanical ventilation, while the oral candidate izicopan advances in clinical development for ANCA-associated vasculitis and other indications. The company focuses on complement-mediated inflammatory diseases with significant unmet medical needs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -14.4 | — |
| Q3 2025 | 0 | — | -12.3 | — |
| Q4 2025 | -0 | — | -10.6 | — |
| Q1 2026 | 0 | — | -5.6 | — |
| Q2 2026 | 0 | -100% | -10.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Twelve Seas Investment Company III (TWLV), Galata Acquisition Corp. II (LATA), SUMA Acquisition Corporation (SUMA), Greenland Energy Company (GLND), Pro-Dex, Inc. (PDEX), Jack in the Box Inc. (JACK)